PRESS RELEASES

First Test for Improved IPF Diagnosis Receives Draft Local Coverage Determination Through the MolDx Program SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that it has received a draft Medicare local coverage determination (LCD) for the Envisia

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 29, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has named Angeline (“Angie”) McCabe as vice president, investor relations and corporate communications, effective immediately. In this role, Ms.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 5,750,000 shares of common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 25, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $10.25 per share. The gross proceeds to Veracyte from this offering,

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 24, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte .

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018 . Following the announcement, Veracyte will host a conference call and webcast

The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.